The China Mail - Study shows how fast kilos return after ending weight-loss drugs

USD -
AED 3.672503
AFN 65.503315
ALL 80.118822
AMD 365.101228
ANG 1.789783
AOA 918.000236
ARS 1487.745002
AUD 1.405975
AWG 1.80125
AZN 1.696327
BAM 1.689027
BBD 2.009905
BDT 122.501501
BGN 1.696366
BHD 0.376353
BIF 2983.311384
BMD 1
BND 1.276452
BOB 11.630749
BRL 5.217695
BSD 0.997902
BTN 95.172426
BWP 13.444507
BYN 3.035115
BYR 19600
BZD 2.007055
CAD 1.38664
CDF 2273.000126
CHF 0.81148
CLF 0.023225
CLP 914.089751
CNY 6.743198
CNH 6.739651
COP 3124.9
CRC 448.981178
CUC 1
CUP 26.5
CVE 95.223908
CZK 20.905698
DJF 177.708307
DKK 6.452155
DOP 58.413323
DZD 132.858425
EGP 50.249703
ERN 15
ETB 161.425894
EUR 0.863101
FJD 2.202699
FKP 0.738997
GBP 0.737885
GEL 2.609449
GGP 0.738997
GHS 10.927886
GIP 0.738997
GMD 73.497673
GNF 8766.165073
GTQ 7.61376
GYD 208.747317
HKD 7.846625
HNL 26.751064
HRK 6.501398
HTG 130.529588
HUF 313.07696
IDR 17803.15
ILS 2.954401
IMP 0.738997
INR 95.595497
IQD 1307.282109
IRR 1374587.504253
ISK 122.729873
JEP 0.738997
JMD 158.0345
JOD 0.708999
JPY 159.078
KES 129.250445
KGS 87.449964
KHR 4038.118596
KMF 427.0002
KPW 900.000294
KRW 1414.280261
KWD 0.30873
KYD 0.831624
KZT 463.058356
LAK 22523.133255
LBP 89358.962735
LKR 332.07394
LRD 181.117151
LSL 16.144443
LTL 2.95274
LVL 0.60489
LYD 6.354251
MAD 9.255973
MDL 17.3033
MGA 4296.404406
MKD 53.102195
MMK 2099.787271
MNT 3596.151184
MOP 8.065977
MRU 40.077551
MUR 46.929705
MVR 15.450305
MWK 1730.479427
MXN 17.006053
MYR 4.077051
MZN 63.909685
NAD 16.144304
NGN 1358.295399
NIO 36.728702
NOK 9.43124
NPR 152.279341
NZD 1.691035
OMR 0.384503
PAB 0.997958
PEN 3.365905
PGK 4.482884
PHP 61.551037
PKR 277.181559
PLN 3.717555
PYG 5989.818345
QAR 3.637965
RON 4.5208
RSD 101.221974
RUB 84.00145
RWF 1467.47555
SAR 3.746487
SBD 8.048583
SCR 14.751212
SDG 600.502774
SEK 9.50225
SGD 1.276955
SHP 0.740866
SLE 24.499323
SLL 20969.499227
SOS 570.305922
SRD 37.974501
STD 20697.981008
STN 21.157898
SVC 8.731622
SYP 13001.999906
SZL 16.14239
THB 33.029496
TJS 9.215989
TMT 3.51
TND 2.925732
TOP 2.40776
TRY 47.897502
TTD 6.760999
TWD 31.857497
TZS 2649.985005
UAH 44.643485
UGX 3707.397956
UYU 39.984283
UZS 11880.324535
VES 770.109097
VND 26205
VUV 117.328472
WST 2.734491
XAF 566.469052
XAG 0.015181
XAU 0.000227
XCD 2.70255
XCG 1.798484
XDR 0.707052
XOF 566.473944
XPF 102.991023
YER 237.201206
ZAR 16.15574
ZMK 9001.201522
ZMW 18.860674
ZWL 321.999592
  • RBGPF

    0.0000

    71.34

    0%

  • CMSC

    -0.0250

    21.45

    -0.12%

  • CMSD

    -0.0100

    21.58

    -0.05%

  • RIO

    -0.4100

    95.68

    -0.43%

  • BCE

    0.1500

    23.47

    +0.64%

  • BTI

    -0.2900

    57.06

    -0.51%

  • NGG

    -0.1500

    81.05

    -0.19%

  • BP

    0.2196

    42.53

    +0.52%

  • RYCEF

    0.1300

    20.84

    +0.62%

  • BCC

    -0.8900

    83.24

    -1.07%

  • RELX

    -0.2400

    34.43

    -0.7%

  • GSK

    -0.4785

    49.52

    -0.97%

  • JRI

    0.0635

    12.61

    +0.5%

  • VOD

    0.2000

    16.42

    +1.22%

  • AZN

    -0.7900

    156.45

    -0.5%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: © AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

Y.Parker--ThChM